美国岸阔医药

Ankura Therapeutics is a clinical-stage biotechnology company focused on developing innovative oncology supportive care therapies to improve the quality of life for cancer patients. The company specializes in addressing the side effects of targeted cancer treatments, particularly skin toxicities induced by EGFR inhibitors and other kinase inhibitors. Its lead candidate, ANK-101, is a topical formulation designed to mitigate skin rashes and other dermatological adverse events without interfering with the systemic efficacy of the primary cancer therapy. Ankura aims to fill a significant unmet need in the oncology space by providing effective treatments for treatment-limiting toxicities.